亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

隨州市紅旗化工有限公司  

醫藥原料醫藥中間體原料藥

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:閆先生
  • 電話:0722-3257386
  • 傳真:0722-3257381
  • QQ:1374834438
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 奧硝唑 CAS:16773-42-5
奧硝唑 CAS:16773-42-5
單價 面議對比
詢價 暫無
發貨 湖北隨州市付款后3天內
型號 16773-42-5
過期 長期有效
更新 2020-06-18 10:08
 
詳細信息
奧硝唑
CAS:16773-42-5
文別名 奧尼達唑;1-(3-氯-2-羥基丙基)-2-甲基-5-硝基咪唑
英文名稱:ornidazole
分子量:219.63
EC NO:240-826-0
分子式:C7H10ClN3O3
InChI:InChI=1/C7H10ClN3O3/c1-5-9-3-7(11(13)14)10(5)4-6(12)2-8/h3,6,12H,2,4H2,1H3
含量 99.0~101.0%
標準cp 2003 /USP24
性狀: 白色或微黃色粉末 熔點 85~90 ℃ 薄層檢測 合格 UV 最大吸收 :230nm ± 2nm, 312nm ± 2nm IR 符合標準 溶液顏色和澄清度 澄清,色澤不得深于 Z-3 重金屬 ≤ 20ppm 鐵鹽 ≤ 20ppm 氯化物 ≤ 0.02% 有關物質 ≤ 0.2% 干燥失重 ≤ 0.5% 禁發 硫酸灰分 ≤ 0.2%
 用途; 用作抗厭氧菌及抗原蟲藥
 包裝:25公斤/桶 
©2025 隨州市紅旗化工有限公司 版權所有   技術支持:化工網   訪問量:31421  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |